Related Experiment Video

Updated: Nov 5, 2025

Author Spotlight: Development of a Method for Identifying Small Molecular Antagonists of β2 Integrin Activation
04:15

Author Spotlight: Development of a Method for Identifying Small Molecular Antagonists of β2 Integrin Activation

Published on: February 2, 2024

2.1K

Expression of activated integrin β7 in multiple myeloma patients

Naoki Hosen1,2, Satoshi Yoshihara3, Hiroyuki Takamatsu4

  • 1Department of Hematology and Oncology, Osaka University Graduate School of Medicine, 2-2 Yamada-Oka, Suita, Osaka, 565-0871, Japan. hnaoki@bldon.med.osaka-u.ac.jp.

International Journal of Hematology
|May 17, 2021
PubMed

Insights

Activated integrin β7 is present in most multiple myeloma cells, even in treated patients. This suggests chimeric antigen receptor (CAR) T-cell therapy targeting integrin β7 could benefit many with relapsed or refractory multiple myeloma.

Area of Science:

  • Oncology
  • Immunology
  • Hematology

Background:

  • Multiple myeloma (MM) remains challenging to cure, necessitating novel therapeutic strategies.
  • Integrin β7 has been identified as constitutively activated in MM cells.
  • Chimeric antigen receptor (CAR) T cells targeting activated integrin β7 demonstrate potent anti-MM effects.

Purpose of the Study:

  • To analyze the expression of activated integrin β7 in bone marrow cells from multiple myeloma patients.
  • To evaluate the potential of activated integrin β7 as a target for CAR T-cell therapy in MM.

Main Methods:

  • Flow cytometry analysis was employed.
  • Bone marrow cells from 137 symptomatic multiple myeloma patients were analyzed for activated integrin β7 expression.

Main Results:

  • Activated integrin β7 was detected in the majority of MM cells (over 80%) in 60/137 (44%) of patients.
  • High expression of activated integrin β7 was observed in MM cells irrespective of prior treatment.
  • Elevated expression was also noted in CD38lo/-CD138-CD19+ B cells, potentially including clonotypic B cells, in MM patients' bone marrow.

Conclusions:

  • Activated integrin β7 is a prevalent targetable antigen in multiple myeloma.
  • CAR T-cell therapy directed against activated integrin β7 holds promise for treating relapsed or refractory MM.
Keywords:
CAR T cellsIntegrinMultiple myeloma

More Related Videos

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.2K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.8K

Related Concept Videos

Activation of Integrins01:15

Activation of Integrins

Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling."
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...
4.2K
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
3.1K
Integrins01:10

Integrins

Animal and protozoan cells do not have cell walls to help maintain shape and provide structural stability. Instead, these eukaryotic cells secrete a sticky mass of carbohydrates and proteins into the spaces between adjacent cells. This network of proteins and molecules is called an extracellular matrix or ECM.
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
4.6K